DOVA Stock Climbs 38% on Buyout News from Swedish Drugmaker

DOVA stock

DOVA stock climbed Monday after Dova Pharmaceuticals (NASDAQ:DOVA) announced a buyout offer from a Swedish drugmaker, Orphan Biovitrum.

Here’s everything we know about the deal, from start to finish.

DOVA Stock Goes Flying on Buyout News

On September 30, Dova Pharmaceuticals said Swedish Orphan Biovitrum will purchase the company for $27.50 a share in cash. If, however, the FDA approves Dova’s primary candidate Doptelet, which is used in the treatment of chemotherapy-induced thrombocytopenia, Orphan Biovitrum (OM: SOBI) will buy the company for an additional $1.50 a share.

“We are extremely pleased to ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.